SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global anticoagulant reversal drugs market is estimated to be valued at US$ 861.6 million in 2021 and is expected to exhibit a CAGR of 14.9% during the forecast period (2021-2028). Among product type, idarucizumab segment is expected to witness highest growth in the global anticoagulant reversal drugs market over the forecast period. Boehringer Ingelheim Pharmaceuticals idarucizumab was authorized as an anticoagulant reversal medication for individuals taking Pradaxa after emergency surgery or life-threatening bleeding. The availability of these anticoagulation reversal medicines, doctors and patients are more confident in adopting such therapeutic options, increasing demand for anticoagulant reversal therapies, therefore boosting the demand for anticoagulant reversal drugs. Based on distribution channel, hospital pharmacy segment is expected to exhibit highest growth rate in the global anticoagulant reversal drugs market over the forecast period.

Source: The North Africa Journal November 15, 2021 14:37 UTC